BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsConference / presentation

ZUG , Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual

Related news

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRSPCRISPR Therapeutics2026-04-07 12:00 EST

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SANASana Biotechnology2026-05-05 20:05 EST

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

CRBUCaribou2026-05-27 20:05 EST

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

CRBUCaribou2026-06-29 12:00 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

VYGRVoyager Therapeutics2026-06-11 20:01 EST

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

KRYSKrystal Biotech2026-05-07 12:00 EST

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

VYGRVoyager Therapeutics2026-06-29 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-04-07 12:00 EST

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
59.50 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States